The observation that an inflammatory state compromises therapy of anemia in MDS patients is not new and could be also demonstrated for tumor necrosis factor-alpha and IL-1β in the context of ESA treatment [31,32]. This evidence concerns the gene IL1B and myelodysplastic syndrome.